These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30130133)

  • 1. Sensitivity and drug tolerance of antidrug antibody assays in relation to positive control characteristics.
    Egging D; Verhagen J; Laat-Arts K; Wit B; Boekel TV; Buurman M; Eigenhuijsen J; Lubbers-Geuijen K; Mulder R
    Bioanalysis; 2018 Aug; 10(16):1289-1306. PubMed ID: 30130133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody.
    Xiang Y; Parng C; Olson K; Seletskaia E; Gorovits B; Jani D; Caiazzo T; Joyce A; Donley J
    AAPS J; 2019 Mar; 21(3):46. PubMed ID: 30927117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays.
    Zoghbi J; Xu Y; Grabert R; Theobald V; Richards S
    J Immunol Methods; 2015 Nov; 426():62-9. PubMed ID: 26255760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of a Ligand-Binding Neutralizing Antibody Assay for Benralizumab: Comparison with an Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Cell-Based Assay.
    Wu Y; Akhgar A; Li JJ; Yu B; Chen C; Lee N; White WI; Roskos LK
    AAPS J; 2018 Mar; 20(3):49. PubMed ID: 29541868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidrug antibody detection for adalimumab depends on the type of assay used: an experimental approach to help clinicians interpret diagnostic data.
    Ruwaard J; Marsman AF; Nurmohamed MT; van der Horst-Bruinsma IE; Te Velthuis H; Bloem K; de Vries A; Rispens T; Wolbink G
    Clin Exp Rheumatol; 2019; 37(5):756-761. PubMed ID: 30943139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis.
    Adedokun OJ; Gunn GR; Leu JH; Gargano C; Xu Z; Sandborn WJ; Rutgeerts P; Shankar G
    Inflamm Bowel Dis; 2019 Aug; 25(9):1532-1540. PubMed ID: 30753466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel drug and soluble target tolerant antidrug antibody assay for therapeutic antibodies bearing the P329G mutation.
    Wessels U; Schick E; Ritter M; Kowalewsky F; Heinrich J; Stubenrauch K
    Bioanalysis; 2017 Jun; 9(11):849-859. PubMed ID: 28517957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients.
    Bloem K; van Leeuwen A; Verbeek G; Nurmohamed MT; Wolbink GJ; van der Kleij D; Rispens T
    J Immunol Methods; 2015 Mar; 418():29-38. PubMed ID: 25637408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic study of the effect of low pH acid treatment on anti-drug antibodies specific for a domain antibody therapeutic: Impact on drug tolerance, assay sensitivity and post-validation method assessment of ADA in clinical serum samples.
    Kavita U; Duo J; Crawford SM; Liu R; Valcin J; Gleason C; Dong H; Gadkari S; Dodge RW; Pillutla RC; DeSilva BS
    J Immunol Methods; 2017 Sep; 448():91-104. PubMed ID: 28625864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An electrochemiluminescence (ECL)-based assay for the specific detection of anti-drug antibodies of the IgE isotype.
    Wu Y; Liu X; Chen Y; Woods R; Lee N; Yang H; Chowdhury P; Roskos LK; White WI
    J Pharm Biomed Anal; 2013 Dec; 86():73-81. PubMed ID: 23988731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies to estimate and improve drug tolerance in anti-drug antibody assays.
    Bütikofer L; Lemaillet G; Faust H
    Bioanalysis; 2012 Aug; 4(16):1999-2012. PubMed ID: 22946916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Collaborative study using common samples to evaluate the performance of anti-drug antibody assays constructed by different companies.
    Niimi S; Nishimiya K; Nishidate M; Saito T; Minoura K; Kadotsuji K; Shimakura J; Shigemizu H; Hosogi J; Adachi M; Hashimoto T; Mori T; Harada H; Yamamoto KI; Nakamura T; Nomura T; Yamaguchi I; Sonehara K; Ishii-Watabe A; Kawasaki N
    Drug Metab Pharmacokinet; 2018 Apr; 33(2):125-132. PubMed ID: 29610053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet(®) biolayer interferometry.
    Li J; Schantz A; Schwegler M; Shankar G
    J Pharm Biomed Anal; 2011 Jan; 54(2):286-94. PubMed ID: 20869832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel data analysis methods to overcome cut point challenges and enable comprehensive assessment of antidrug binding activity in confirmatory assays.
    Mikulskis A; Yeung D; Chen W; Mehta D; Amaravadi L
    J Immunol Methods; 2013 Jun; 392(1-2):38-48. PubMed ID: 23541489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
    Stubenrauch K; Wessels U; Essig U; Vogel R; Schleypen J
    J Pharm Biomed Anal; 2010 Jun; 52(2):249-54. PubMed ID: 20083366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.
    van Brummelen EM; Ros W; Wolbink G; Beijnen JH; Schellens JH
    Oncologist; 2016 Oct; 21(10):1260-1268. PubMed ID: 27440064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altering drug tolerance of surface plasmon resonance assays for the detection of anti-drug antibodies.
    Barbosa MD; Gokemeijer J; Martin AD; Bush A
    Anal Biochem; 2013 Oct; 441(2):174-9. PubMed ID: 23886888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of a bifunctional drug in the presence of an immune response: a ligand-binding assay specific for 'active' drug.
    Staack RF; Jordan G; Viert M; Schäfer M; Papadimitriou A; Heinrich J
    Bioanalysis; 2015 Dec; 7(24):3097-106. PubMed ID: 26484402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Confirmatory cut point has limited ability to make accurate classifications in immunogenicity assays.
    Kubiak RJ; Arends RH; Lee N; Liang M; Zhang J; Roskos LK
    Bioanalysis; 2020 Feb; 12(4):245-256. PubMed ID: 32090586
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease: Distinct Clinical Implications Revealed by a Novel Assay.
    Weisshof R; Ungar B; Blatt A; Dahan A; Pressman S; Waterman M; Kopylov U; Ben-Horin S; Chowers Y
    Inflamm Bowel Dis; 2016 Jul; 22(7):1655-61. PubMed ID: 27120567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.